Evidence map›Paper›PMID 41035547›Full record

ReviewTechnical innovations & patient support in radiation oncology2025

Patient perspectives on participation in the Danish Breast Cancer Group Proton Trial: A qualitative research study.

Kristine W Høgsbjerg, Anne W Kristensen, Mette Møller, Else Maae, Maja V Maraldo, Louise W Matthiessen, Sami Al-Rawi, Mette H Nielsen, Cai Grau, Birgitte V Offersen

Abstract readReview
In one paragraph

Review in Technical innovations & patient support in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kristine W HøgsbjergDepartment of Experimental Clinical Oncology, Department of Oncology, Palle Juul-Jensens Boulevard 99, 8200 Aarhus N, Aarhus University Hospital, Denmark.
Anne W KristensenDanish Centre for Particle Therapy, Aarhus University Hospital, Denmark.
Mette MøllerDepartment of Oncology, Aalborg University Hospital, Denmark.
Else MaaeDepartment of Oncology, Vejle Hospital, University of Southern Denmark, Denmark.
Maja V MaraldoDepartment of Oncology, Copenhagen University Hospital, Rigshospitalet, Denmark.
Louise W MatthiessenDepartment of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Denmark.
Sami Al-RawiDepartment of Clinical Oncology and Palliative Care, Zealand University Hospital, Denmark.
Mette H NielsenDepartment of Oncology, Odense University Hospital, Denmark.
Cai GrauDanish Centre for Particle Therapy, Aarhus University Hospital, Denmark.
Birgitte V OffersenDepartment of Experimental Clinical Oncology, Department of Oncology, Palle Juul-Jensens Boulevard 99, 8200 Aarhus N, Aarhus University Hospital, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and purpose: Participation in clinical trials is essential to advancing oncological treatments, yet equitable trial access remains challenging. Diverse patient inclusion strengthens external validity and enhances the generalisability of trial outcomes. However, barriers to trial participation persist, and the factors influencing patient enrolment are not fully understood. This study investigates the patient perspective on participation in the Danish Breast Cancer Group (DBCG) Proton Trial. Materials and methods: Patients eligible for the DBCG Proton Trial were invited to participate in interviews. Patients were selected to ensure geographical and perspective-based diversity, including randomised and non-randomised patients from eight radiotherapy clinics in Denmark. Semi-structured interviews were conducted via telephone, transcribed, and analysed using an inductive approach to identify the patient perspective on trial participation. Results: A total of fifteen patients were interviewed. The analysis identified five themes encompassing patients' motivators and barriers to trial participation: distance to the treatment facility, timing of trial information, decisional support, clinical equipoise and patient needs. These factors were reported by both randomised and non-randomised patients. Interpretation: Participation in the DBCG Proton Trial was determined by both logistical and personal factors. Distance to the proton treatment facility was the most important barrier, while the potential for reduced late effects was the main motivator. The decision was difficult for most patients, often guided by one dominant concern rather than a balanced consideration of multiple factors. These findings suggest that improved trial communication, decisional support, and attention to geographical barriers are essential for promoting equitable participation in clinical trials.

Indexed as

BarriersBreast cancerProton therapyTrial participation

Identifiers

PMID41035547
PMCPMC12482280

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.